Selected research
Industry Research
PET Radiopharmaceuticals Industry Research Report 2026
Market perspective
The global PET Radiopharmaceuticals market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for PET Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for PET Radiopharmaceuticals is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for PET Radiopharmaceuticals is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of PET Radiopharmaceuticals include Cardinal Health Inc. (U.S.), Bayer AG (Germany), Nordion, Inc. (Canada), Mallinckrodt plc (Ireland), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), GE Healthcare (U.K.), Eczacibasi-Monrol Nuclear Products (Turkey) and Bracco Imaging S.p.A (Italy), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global PET Radiopharmaceuticals market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
PET Radiopharmaceuticals Market by Company
Cardinal Health Inc. (U.S.)
Bayer AG (Germany)
Nordion, Inc. (Canada)
Mallinckrodt plc (Ireland)
Lantheus Medical Imaging, Inc. (U.S.)
IBA Molecular Imaging (Belgium)
GE Healthcare (U.K.)
Eczacibasi-Monrol Nuclear Products (Turkey)
Bracco Imaging S.p.A (Italy)
Advanced Accelerator Applications S.A. (France)
PET Radiopharmaceuticals Segment by Type
F-18
Ru-82
Others
PET Radiopharmaceuticals Segment by Application
Neurology
Cardiology
Oncology
Others
PET Radiopharmaceuticals Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PET Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PET Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PET Radiopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of PET Radiopharmaceuticals manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of PET Radiopharmaceuticals by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of PET Radiopharmaceuticals in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- F-18
- Ru-82
- Others
Applications
- Neurology
- Cardiology
- Oncology
- Others
Companies covered
- Cardinal Health Inc. (U.S.)
- Bayer AG (Germany)
- Nordion, Inc. (Canada)
- Mallinckrodt plc (Ireland)
- Lantheus Medical Imaging, Inc. (U.S.)
- IBA Molecular Imaging (Belgium)
- GE Healthcare (U.K.)
- Eczacibasi-Monrol Nuclear Products (Turkey)
- Bracco Imaging S.p.A (Italy)
- Advanced Accelerator Applications S.A. (France)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global PET Radiopharmaceuticals Market Size (2021-2032)
- 2.2.2 Global PET Radiopharmaceuticals Sales (2021-2032)
- 2.2.3 Global PET Radiopharmaceuticals Market Average Price (2021-2032)
- 2.3 PET Radiopharmaceuticals by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 F-18
- 2.3.3 Ru-82
- 2.3.4 Others
- 2.4 PET Radiopharmaceuticals by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Neurology
- 2.4.3 Cardiology
- 2.4.4 Oncology
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global PET Radiopharmaceuticals Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global PET Radiopharmaceuticals Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global PET Radiopharmaceuticals Revenue of Manufacturers (2021-2026)
- 3.4 Global PET Radiopharmaceuticals Average Price by Manufacturers (2021-2026)
- 3.5 Global PET Radiopharmaceuticals Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of PET Radiopharmaceuticals, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of PET Radiopharmaceuticals, Product Type & Application
- 3.8 Global Manufacturers of PET Radiopharmaceuticals, Established Date
- 3.9 Global PET Radiopharmaceuticals Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Cardinal Health Inc. (U.S.)
- 4.1.1 Cardinal Health Inc. (U.S.) Company Information
- 4.1.2 Cardinal Health Inc. (U.S.) Business Overview
- 4.1.3 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio
- 4.1.5 Cardinal Health Inc. (U.S.) Recent Developments
- 4.2 Bayer AG (Germany)
- 4.2.1 Bayer AG (Germany) Company Information
- 4.2.2 Bayer AG (Germany) Business Overview
- 4.2.3 Bayer AG (Germany) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bayer AG (Germany) PET Radiopharmaceuticals Product Portfolio
- 4.2.5 Bayer AG (Germany) Recent Developments
- 4.3 Nordion, Inc. (Canada)
- 4.3.1 Nordion, Inc. (Canada) Company Information
- 4.3.2 Nordion, Inc. (Canada) Business Overview
- 4.3.3 Nordion, Inc. (Canada) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Nordion, Inc. (Canada) PET Radiopharmaceuticals Product Portfolio
- 4.3.5 Nordion, Inc. (Canada) Recent Developments
- 4.4 Mallinckrodt plc (Ireland)
- 4.4.1 Mallinckrodt plc (Ireland) Company Information
- 4.4.2 Mallinckrodt plc (Ireland) Business Overview
- 4.4.3 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Product Portfolio
- 4.4.5 Mallinckrodt plc (Ireland) Recent Developments
- 4.5 Lantheus Medical Imaging, Inc. (U.S.)
- 4.5.1 Lantheus Medical Imaging, Inc. (U.S.) Company Information
- 4.5.2 Lantheus Medical Imaging, Inc. (U.S.) Business Overview
- 4.5.3 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio
- 4.5.5 Lantheus Medical Imaging, Inc. (U.S.) Recent Developments
- 4.6 IBA Molecular Imaging (Belgium)
- 4.6.1 IBA Molecular Imaging (Belgium) Company Information
- 4.6.2 IBA Molecular Imaging (Belgium) Business Overview
- 4.6.3 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Product Portfolio
- 4.6.5 IBA Molecular Imaging (Belgium) Recent Developments
- 4.7 GE Healthcare (U.K.)
- 4.7.1 GE Healthcare (U.K.) Company Information
- 4.7.2 GE Healthcare (U.K.) Business Overview
- 4.7.3 GE Healthcare (U.K.) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 GE Healthcare (U.K.) PET Radiopharmaceuticals Product Portfolio
- 4.7.5 GE Healthcare (U.K.) Recent Developments
- 4.8 Eczacibasi-Monrol Nuclear Products (Turkey)
- 4.8.1 Eczacibasi-Monrol Nuclear Products (Turkey) Company Information
- 4.8.2 Eczacibasi-Monrol Nuclear Products (Turkey) Business Overview
- 4.8.3 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Product Portfolio
- 4.8.5 Eczacibasi-Monrol Nuclear Products (Turkey) Recent Developments
- 4.9 Bracco Imaging S.p.A (Italy)
- 4.9.1 Bracco Imaging S.p.A (Italy) Company Information
- 4.9.2 Bracco Imaging S.p.A (Italy) Business Overview
- 4.9.3 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Product Portfolio
- 4.9.5 Bracco Imaging S.p.A (Italy) Recent Developments
- 4.10 Advanced Accelerator Applications S.A. (France)
- 4.10.1 Advanced Accelerator Applications S.A. (France) Company Information
- 4.10.2 Advanced Accelerator Applications S.A. (France) Business Overview
- 4.10.3 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Product Portfolio
- 4.10.5 Advanced Accelerator Applications S.A. (France) Recent Developments
5 Global PET Radiopharmaceuticals Market Scenario by Region
- 5.1 Global PET Radiopharmaceuticals Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global PET Radiopharmaceuticals Sales by Region: 2021-2032
- 5.2.1 Global PET Radiopharmaceuticals Sales by Region: 2021-2026
- 5.2.2 Global PET Radiopharmaceuticals Sales by Region: 2027-2032
- 5.3 Global PET Radiopharmaceuticals Revenue by Region: 2021-2032
- 5.3.1 Global PET Radiopharmaceuticals Revenue by Region: 2021-2026
- 5.3.2 Global PET Radiopharmaceuticals Revenue by Region: 2027-2032
- 5.4 North America PET Radiopharmaceuticals Market Facts & Figures by Country
- 5.4.1 North America PET Radiopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America PET Radiopharmaceuticals Sales by Country (2021-2032)
- 5.4.3 North America PET Radiopharmaceuticals Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe PET Radiopharmaceuticals Market Facts & Figures by Country
- 5.5.1 Europe PET Radiopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe PET Radiopharmaceuticals Sales by Country (2021-2032)
- 5.5.3 Europe PET Radiopharmaceuticals Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific PET Radiopharmaceuticals Market Facts & Figures by Country
- 5.6.1 Asia Pacific PET Radiopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific PET Radiopharmaceuticals Sales by Country (2021-2032)
- 5.6.3 Asia Pacific PET Radiopharmaceuticals Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America PET Radiopharmaceuticals Market Facts & Figures by Country
- 5.7.1 South America PET Radiopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America PET Radiopharmaceuticals Sales by Country (2021-2032)
- 5.7.3 South America PET Radiopharmaceuticals Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa PET Radiopharmaceuticals Market Facts & Figures by Country
- 5.8.1 Middle East and Africa PET Radiopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa PET Radiopharmaceuticals Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa PET Radiopharmaceuticals Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global PET Radiopharmaceuticals Sales by Type (2021-2032)
- 6.1.1 Global PET Radiopharmaceuticals Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global PET Radiopharmaceuticals Sales Market Share by Type (2021-2032)
- 6.2 Global PET Radiopharmaceuticals Revenue by Type (2021-2032)
- 6.2.1 Global PET Radiopharmaceuticals Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global PET Radiopharmaceuticals Revenue Market Share by Type (2021-2032)
- 6.3 Global PET Radiopharmaceuticals Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global PET Radiopharmaceuticals Sales by Application (2021-2032)
- 7.1.1 Global PET Radiopharmaceuticals Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global PET Radiopharmaceuticals Sales Market Share by Application (2021-2032)
- 7.2 Global PET Radiopharmaceuticals Revenue by Application (2021-2032)
- 7.2.1 Global PET Radiopharmaceuticals Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global PET Radiopharmaceuticals Revenue Market Share by Application (2021-2032)
- 7.3 Global PET Radiopharmaceuticals Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 PET Radiopharmaceuticals Value Chain Analysis
- 8.1.1 PET Radiopharmaceuticals Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 PET Radiopharmaceuticals Production Mode & Process
- 8.2 PET Radiopharmaceuticals Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 PET Radiopharmaceuticals Distributors
- 8.2.3 PET Radiopharmaceuticals Customers
9 Global PET Radiopharmaceuticals Analyzing Market Dynamics
- 9.1 PET Radiopharmaceuticals Industry Trends
- 9.2 PET Radiopharmaceuticals Industry Drivers
- 9.3 PET Radiopharmaceuticals Industry Opportunities and Challenges
- 9.4 PET Radiopharmaceuticals Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst